AI Healthcare Stocks Gaining Attention In Australia For Real World Hospital Use

Rising inflation pressures, higher energy costs, and uncertain interest rate paths are keeping markets on edge, but they are also pushing investors to look for themes with clear, long-term real-world use cases. Transformative AI Healthcare Stocks focus on companies using artificial intelligence to help doctors spot disease earlier, personalize treatment, and run hospitals more efficiently, while also supporting remote care and faster drug research. This screener narrows a complex field into a curated list of AI healthcare stocks that align with these trends. The rest of this article highlights three of the stocks from that list.

ImExHS (ASX:IME)

Overview: ImExHS is a Sydney based healthcare technology company that provides cloud based medical imaging software for radiology, cardiology and pathology, alongside outsourced and teleradiology services for hospitals and clinics across multiple countries.

Operations: ImExHS generates about A$10.0m from Software and A$19.2m from Radiology (partly offset by A$0.2m of intersegment eliminations), with its revenue concentrated in Latin America at approximately A$29.0m.

Market Cap: A$16.8m

ImExHS may be of interest if you are looking at how AI and cloud software are being used in everyday hospital workflows, not just experimental projects. Its Aquila+ imaging platform and radiology services are closely linked, so developments in AI driven efficiency can affect both software margins and outsourced reporting quality. At the same time, heavy exposure to Latin American healthcare systems, funding that relies on external borrowing and governance questions around board independence mean the situation involves risk. The upcoming CFO change in Colombia adds another factor that could either strengthen execution or introduce short term uncertainty.

ImExHS combines AI imaging, cloud delivery and outsourced radiology into a single story, but the key question is whether the current share price reflects that mix of opportunity and funding risk. Get the full picture in the DCF valuation analysis for ImExHS

Singular Health Group (ASX:SHG)

Overview: Singular Health Group is an Australian medical technology company that turns traditional 2D scans into interactive 3D models through its 3DiCom platform, helping clinicians and patients better visualise anatomy for diagnosis and treatment planning. It also offers secure file transfer and cloud based AI tools for medical imaging insights.

Operations: Singular Health Group generates approximately A$1.0m from the provision and development of its medical technology, with around A$0.5m of this attributed to the United States.

Market Cap: A$61.8m

Singular Health Group sits at the intersection of 3D medical imaging and cloud based AI, which is a segment many investors consider when looking at Transformative AI Healthcare Stocks. The current numbers indicate that revenue is still under A$1.0m, the company is unprofitable with declining earnings and a high P/B ratio, and a short cash runway combined with reliance on external borrowing raises funding and liquidity questions. At the same time, an experienced and largely independent board supports a focused push on volumetric rendering and AI in the cloud, areas that may benefit from increased adoption. The key consideration for investors is how these risks compare with the potential role of its 3D and AI platform in clinical workflows.

Singular Health Group’s tiny revenue base and high P/B ratio mean expectations are already loaded, but the real tension is whether its 3D and AI platform can justify that optimism. See how the analysis report for Singular Health Group reshapes the risk reward picture.

Artrya (ASX:AYA)

Overview: Artrya is an Australian medical technology company that uses artificial intelligence to analyse coronary CT angiography scans, helping clinicians detect and manage coronary artery disease and identify patients at risk of a heart attack through its cloud based Salix software suite.

Operations: Artrya currently generates about A$0.03m in revenue from the development of its AI driven CCTA image analysis technology, all of which is earned in Australia.

Market Cap: A$846.9m

Artrya attracts attention in the Transformative AI Healthcare Stocks theme because it is trying to turn AI powered cardiac imaging into a full platform, with potential revenue from anatomy, plaque and blood flow analysis, supported by a large real world SAPPHIRE study and a cash position of about A$76.5m with no debt. At the same time, customer receipts are still small, operating cash outflows are sizeable, and US cardiac imaging is competitive, so a lot rests on successful FDA clearance, hospital adoption and careful spending. The recent appointment of experienced healthcare CFO Clayton Hatch adds an extra layer of interest for investors watching how Artrya turns its technology and balance sheet into a scalable business model.

Artrya’s large cash balance with no debt and tiny current revenue base creates an unusual setup. The real story sits in how that capital, clinical data and analyst forecasts for Artrya could intersect next.

The three Transformative Artificial intelligence (AI) Healthcare Stocks in this article are just a starting point, as the full Transformative Artificial intelligence (AI) Healthcare Stocks screener has identified 5 more companies with equally compelling narratives around diagnostics, personalized medicine, hospital efficiency, remote care and research. Use Simply Wall St to identify, compare and analyze the specific catalysts and narratives that matter most to you so you can focus on the highest conviction AI healthcare ideas across this theme.

Take Control of Your Investment Journey

If Artrya or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Beyond AI Healthcare?

Fresh stock ideas do not stay under the radar for long, and momentum can shift quickly as markets react. Scan these focused lists before the crowd and act now.

• Target reliable cash generators with a 9 high quality undervalued stocks that highlights businesses where balance sheets and cash flows already support the current share prices.
• Ride structural trends in power demand through the 35 power grid technology and infrastructure stocks featuring companies tied to grid upgrades, electrification and critical infrastructure build outs.
• Catch secular automation tailwinds using the 32 robotics and automation stocks focused on stocks building robots, sensors and software that keep factories, warehouses and services running efficiently.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com